LOGIN  |  REGISTER
C4 Therapeutics

Orthofix Medical Reports Fourth Quarter and Full Year 2023 Results

March 05, 2024 | Last Trade: US$17.34 0.01 0.06

Recent Highlights

  • Fourth quarter 2023 net sales of $200.4 million, an increase of 64% on a reported basis and 7% on a pro forma constant currency basis
  • Bone Growth Therapies net sales growth of 15% for the fourth quarter of 2023, marking four consecutive quarters with double-digit net sales increases, representing the strongest quarter of Bone Growth Therapies sales in the history of Orthofix
  • U.S. Orthopedic net sales growth of 11% for the full year 2023
  • U.S. spine fixation1 net sales growth of 13.5% in Q4 2023 with net distributor additions since the third quarter of 2023
  • Fourth quarter 2023 net loss of $22 million; Non-GAAP Adjusted EBITDA of $20 million, or 10% of sales, representing 96% growth over the fourth quarter of 2022
  • Achieved $32 million in annualized merger-related synergies for the full year ended December 31, 2023

LEWISVILLE, Texas / Mar 05, 2024 / Business Wire / Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the fourth quarter and year ended December 31, 2023, and issued guidance for the full year 2024.

Fourth quarter net sales were $200.4 million, an increase of 64% on a reported basis and 7% on a pro forma constant currency basis. Net loss was $(22.2) million and earnings per share ("EPS") was $(0.59) on a reported basis, representing an improvement of 19% when compared to pro forma results for the prior year period. Non-GAAP adjusted EBITDA was $19.6 million for the fourth quarter, representing 96% growth over pro forma results for the fourth quarter of 2022.

Full year net sales were $746.6 million, an increase of 62% on a reported basis and 6% on a pro forma constant currency basis. Net loss was $(151.4) million and EPS was $(4.12). Non-GAAP adjusted EBITDA was $46.3 million for the full year, representing 69% growth over pro forma results for the full year of 2022.

“We are pleased to report another quarter of strong performance as Orthofix completes its first full year as a combined company with SeaSpine. We delivered accelerated growth exiting 2023 and demonstrated resilience, increased internal efficiencies and cost synergies,” said Massimo Calafiore, President and Chief Executive Officer of Orthofix. “I am thrilled to join Orthofix at such a pivotal moment in the Company’s story, wherein the business fundamentals are strong, we are well positioned to deliver profitable growth in 2024, and we are continuing to accelerate our leverage on revenue. After reflecting on my first two months in this role, it is evident that Orthofix’s balanced and complementary product mix offers a differentiated advantage across multiple markets. I look forward to leveraging that unique portfolio platform to drive future value through profitable growth.”

1 Spine fixation is comprised of the Company's Spinal Implants product category, excluding motion preservation product offerings

Financial Results Overview

Fourth Quarter 2023 Net Sales and Financial Results

The following table provides net sales by major product category by reporting segment on a reporting basis:

 

 

Three Months Ended December 31,

 

(Unaudited, U.S. Dollars, in millions)

 

2023

 

 

2022

 

 

Change

 

 

Constant
Currency
Change

 

Bone Growth Therapies

 

$

58.8

 

 

$

51.0

 

 

 

15.3

%

 

 

15.3

%

Spinal Implants, Biologics, and Enabling Technologies

 

 

111.0

 

 

 

42.5

 

 

 

161.2

%

 

 

160.7

%

Global Spine

 

 

169.8

 

 

 

93.5

 

 

 

81.6

%

 

 

81.4

%

Global Orthopedics

 

 

30.6

 

 

 

28.7

 

 

 

6.8

%

 

 

2.7

%

Net sales

 

$

200.4

 

 

$

122.2

 

 

 

64.0

%

 

 

62.9

%

Further, the following table provides net sales by major product category by reporting segment on a pro forma basis:

 

 

Three Months Ended December 31,

 

(Unaudited, U.S. Dollars, in millions)

 

2023

 

 

2022 Pro Forma

 

 

Change

 

 

Constant
Currency
Change

 

Bone Growth Therapies

 

$

58.8

 

 

$

51.0

 

 

 

15.3

%

 

 

15.3

%

U.S. Spinal Implants, Biologics and Enabling Technologies

 

 

100.6

 

 

 

96.4

 

 

 

4.4

%

 

 

4.4

%

International Spinal Implants, Biologics, and Enabling Technologies

 

 

10.4

 

 

 

10.3

 

 

 

0.7

%

 

 

0.1

%

Total Spinal Implants, Biologics, and Enabling Technologies

 

 

111.0

 

 

 

106.7

 

 

 

4.0

%

 

 

4.0

%

Global Spine

 

 

169.8

 

 

 

157.7

 

 

 

7.7

%

 

 

7.6

%

Global Orthopedics

 

 

30.6

 

 

 

28.7

 

 

 

6.8

%

 

 

2.7

%

Net sales

 

$

200.4

 

 

$

186.4

 

 

 

7.5

%

 

 

6.9

%

Gross margins were 68.2% for the fourth quarter ended December 31, 2023 and were 72.2% on a non-GAAP adjusted basis compared to pro-forma non-GAAP adjusted gross margin of 68.9% in the prior year period.

Net loss was $(22.2) million, or $(0.59) per share, compared to pro forma net loss of $(26.0) million, or $(0.73) per share in the prior year period. Non-GAAP adjusted EBITDA was $19.6 million, or 9.8% of net sales, compared to pro forma non-GAAP adjusted EBITDA of $10.0 million, or 5.4% of pro forma net sales, in the prior year period.

Full Year 2023 Net Sales and Financial Results

The following table provides net sales by major product category by reporting segment on a reporting basis:

 

 

Year Ended December 31,

 

(Unaudited, U.S. Dollars, in millions)

 

2023

 

 

2022

 

 

Change

 

 

Constant
Currency
Change

 

Bone Growth Therapies

 

$

212.5

 

 

$

187.2

 

 

 

13.5

%

 

 

13.5

%

Spinal Implants, Biologics, and Enabling Technologies

 

 

418.8

 

 

 

166.0

 

 

 

152.4

%

 

 

152.4

%

Global Spine

 

 

631.3

 

 

 

353.2

 

 

 

78.8

%

 

 

78.7

%

Global Orthopedics

 

 

115.3

 

 

 

107.5

 

 

 

7.2

%

 

 

5.2

%

Net sales

 

$

746.6

 

 

$

460.7

 

 

 

62.1

%

 

 

61.6

%

Further, the following table provides net sales by major product category by reporting segment on a pro forma basis:

 

 

Year Ended December 31,

(Unaudited, U.S. Dollars, in millions)

 

2023

 

 

2022 Pro Forma

 

 

Change

 

Constant
Currency
Change

Bone Growth Therapies

 

$

212.5

 

 

$

187.2

 

 

 

13.5

%

 

 

13.5

%

U.S. Spinal Implants, Biologics and Enabling Technologies

 

 

379.4

 

 

 

352.5

 

 

 

7.6

%

 

 

7.6

%

International Spinal Implants, Biologics, and Enabling Technologies

 

 

39.4

 

 

 

53.6

 

 

 

(26.5

%)

 

 

(26.6

%)

Total Spinal Implants, Biologics, and Enabling Technologies**

 

 

418.8

 

 

 

406.0

 

 

 

3.1

%

 

 

3.1

%

Global Spine

 

 

631.3

 

 

 

593.3

 

 

 

6.4

%

 

 

6.4

%

Global Orthopedics

 

 

115.3

 

 

 

107.5

 

 

 

7.2

%

 

 

5.2

%

Net sales***

 

$

746.6

 

 

$

700.8

 

 

 

6.5

%

 

 

6.2

%

** Pro forma net sales for 2022 for Spinal Implants, Biologics, and Enabling Technologies include the impact of final Spinal Implant stocking orders to European distributors prior to SeaSpine's exit from that market. Excluding the impact of these transactions, net sales growth for this product category was 6.3% on a pro forma reported basis and pro forma constant currency basis.

*** Pro forma net sales for 2022 include the impact of final Spinal Implant stocking orders to European distributors prior to SeaSpine's exit from that market. Excluding the impact of these transactions, net sales growth was 8.4% on a pro forma reported basis and 8.1% on a pro forma constant currency basis.

Gross margins were 65.1% and were 71.4% on a non-GAAP adjusted basis compared to pro forma non-GAAP adjusted gross margin of 68.7% in the prior year.

Net loss was $(151.4) million, or $(4.12) per share, compared to pro forma net loss of $(84.8) million, or $(2.39) per share in the prior year. Non-GAAP adjusted EBITDA was $46.3 million, or 6.2% of net sales, compared to pro forma non-GAAP adjusted EBITDA of $27.4 million, or 3.9% of pro forma net sales, in the prior year period.

Liquidity

As of December 31, 2023, cash, cash equivalents, and restricted cash totaled $37.8 million compared to $50.7 million on December 31, 2022. As of December 31, 2023, the Company had $100.0 million in borrowings outstanding under its four year $150.0 million Financing Agreement. The Company subsequently borrowed an additional $15.0 million in January 2024.

Business Outlook

The Company is providing 2024 full year guidance as follows:

  • Net sales to range between $785 million to $795 million, representing implied growth of 5% to 7% year-over-year on a constant currency basis. These expectations are based on the current foreign currency exchange rates and do not take into account any additional potential exchange rate changes that may occur this year.
  • Non-GAAP adjusted EBITDA of $62 million to $67 million, representing a $15.7 million to $20.7 million increase, over the full year 2023
  • Exit Q4 2024 free cash flow positive

Conference Call

Orthofix will host a conference call today at 4:30 PM Eastern time to discuss the Company's financial results for the year ended December 31, 2023. Interested parties may access the conference call by dialing (888) 330-2508 in the U.S. and Canada, and (240) 789-2735 in all other locations, and referencing the access code 9556380. A replay of the call will be available for three weeks by dialing (800) 770-2030 in the U.S. and Canada, and (647) 362-9199 in all other locations, and entering the access code 9556380. A webcast of the conference call may be accessed at ir.Orthofix.com.

About Orthofix

Orthofix is a leading global spine and orthopedics company with a comprehensive portfolio of biologics, innovative spinal hardware, bone growth therapies, specialized orthopedic solutions and a leading surgical navigation system. Its products are distributed in more than 60 countries worldwide.

The Company is headquartered in Lewisville, Texas and has primary offices in Carlsbad, CA, with a focus on spine and biologics product innovation and surgeon education, and Verona, Italy, with an emphasis on product innovation, production, and medical education for orthopedics. The combined company’s global R&D, commercial and manufacturing footprint also includes facilities and offices in Irvine, CA, Toronto, Canada, Sunnyvale, CA, Wayne, PA, Olive Branch, MS, Maidenhead, UK, Munich, Germany, Paris, France, and São Paulo, Brazil. For more information, please visit www.orthofix.com.

Forward-Looking Statements

This communication contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, relating to our business and financial outlook, which are based on our current beliefs, assumptions, expectations, estimates, forecasts and projections. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “intends,” “predicts,” “potential,” or “continue” or other comparable terminology. Forward-looking statements in this communication include the Company's expectations regarding net sales and adjusted EBITDA for the year ended December 31, 2024. Forward-looking statements are not guarantees of our future performance, are based on our current expectations and assumptions regarding our business, the economy and other future conditions, and are subject to risks, uncertainties and changes in circumstances that are difficult to predict, including the risks described in Part I, Item 1A under the heading Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Form 10-K”). Factors that could cause future results to differ from those expressed by forward-looking statements include, but are not limited to, (i) our ability to maintain operations to support our customers and patients in the near-term and to capitalize on future growth opportunities, (ii) risks associated with acceptance of surgical products and procedures by surgeons and hospitals, (iii) development and acceptance of new products or product enhancements, (iv) clinical and statistical verification of the benefits achieved via the use of our products, (v) our ability to adequately manage inventory, (vi) our ability to recruit and retain management and key personnel, (vii) global economic instability and potential supply chain disruption caused by Russia’s invasion of Ukraine and resulting sanctions, and (viii) the other risks and uncertainties more fully described in our periodic filings with the Securities and Exchange Commission (the “SEC”). As a result of these various risks, our actual outcomes and results may differ materially from those expressed in these forward-looking statements.

This list of risks, uncertainties, and other factors is not complete. We discuss some of these matters more fully, as well as certain risk factors that could affect our business, financial condition, results of operations, and prospects, in reports we file from time-to-time with the SEC, which are available to read at www.sec.gov. Any or all forward-looking statements that we make may turn out to be wrong (due to inaccurate assumptions that we make or otherwise), and our actual outcomes and results may differ materially from those expressed in these forward-looking statements. You should not place undue reliance on any of these forward-looking statements. Further, any forward-looking statement speaks only as of the date hereof, unless it is specifically otherwise stated to be made as of a different date. We undertake no obligation to update, and expressly disclaim any duty to update, our forward-looking statements, whether as a result of circumstances or events that arise after the date hereof, new information, or otherwise, except as required by law.

The Company is unable to provide expectations of GAAP income (loss) before income taxes, the closest comparable GAAP measures to Adjusted EBITDA (which is a non-GAAP measure), on a forward-looking basis because the Company is unable to predict without unreasonable efforts the ultimate outcome of matters (including acquisition-related expenses, accounting fair value adjustments, and other such items) that will determine the quantitative amount of the items excluded in calculating Adjusted EBITDA, which items are further described in the reconciliation tables and related descriptions below. These items are uncertain, depend on various factors, and could be material to the Company’s results computed in accordance with GAAP.

ORTHOFIX MEDICAL INC.

Condensed Consolidated Statements of Operations

     

 

 

Three Months Ended

 

Year Ended

 

 

December 31,

 

December 31,

(U.S. Dollars, in thousands, except share and per share data)

 

2023

 

 

2022

 

 

2023

 

 

2022

 

 

 

(Unaudited)

 

 

Net sales

 

$

200,415

 

 

$

122,229

 

 

$

746,641

 

 

$

460,713

 

Cost of sales

 

 

63,785

 

 

 

33,053

 

 

 

260,368

 

 

 

123,544

 

Gross profit

 

 

136,630

 

 

 

89,176

 

 

 

486,273

 

 

 

337,169

 

Sales and marketing

 

 

97,749

 

 

 

59,324

 

 

 

385,736

 

 

 

228,810

 

General and administrative

 

 

34,535

 

 

 

25,470

 

 

 

144,659

 

 

 

79,966

 

Research and development

 

 

18,941

 

 

 

13,152

 

 

 

80,231

 

 

 

49,065

 

Acquisition-related amortization and remeasurement

 

 

3,720

 

 

 

2,274

 

 

 

14,757

 

 

 

(7,404

)

Operating loss

 

 

(18,315

)

 

 

(11,044

)

 

 

(139,110

)

 

 

(13,268

)

Interest expense, net

 

 

(4,500

)

 

 

(229

)

 

 

(8,631

)

 

 

(1,288

)

Other income (expense), net

 

 

766

 

 

 

4,286

 

 

 

(938

)

 

 

(3,150

)

Loss before income taxes

 

 

(22,049

)

 

 

(6,987

)

 

 

(148,679

)

 

 

(17,706

)

Income tax expense

 

 

(125

)

 

 

(75

)

 

 

(2,716

)

 

 

(2,043

)

Net loss

 

$

(22,174

)

 

$

(7,062

)

 

$

(151,395

)

 

$

(19,749

)

 

 

 

 

 

 

 

 

 

Net loss per common share:

 

 

 

 

 

 

 

 

Basic

 

$

(0.59

)

 

$

(0.35

)

 

$

(4.12

)

 

$

(0.98

)

Diluted

 

 

(0.59

)

 

 

(0.35

)

 

 

(4.12

)

 

 

(0.98

)

Weighted average number of common shares (in millions):

 

 

 

 

 

 

 

 

Basic

 

 

37.3

 

 

 

20.2

 

 

 

36.7

 

 

 

20.1

 

Diluted

 

 

37.3

 

 

 

20.2

 

 

 

36.7

 

 

 

20.1

 

                 

ORTHOFIX MEDICAL INC.

Condensed Consolidated Balance Sheets

     

(U.S. Dollars, in thousands, except par value data)

 

December 31, 2023

 

December 31, 2022

 

 

 

 

 

Assets

 

 

 

 

Current assets

 

 

 

 

Cash and cash equivalents

 

$

33,107

 

 

$

50,700

 

Restricted cash

 

 

4,650

 

 

 

 

Accounts receivable, net of allowances of $7,130 and $6,419, respectively

 

 

128,098

 

 

 

82,857

 

Inventories

 

 

222,166

 

 

 

100,150

 

Prepaid expenses and other current assets

 

 

32,422

 

 

 

22,283

 

Total current assets

 

 

420,443

 

 

 

255,990

 

Property, plant, and equipment, net

 

 

159,060

 

 

 

58,229

 

Intangible assets, net

 

 

117,490

 

 

 

47,388

 

Goodwill

 

 

194,934

 

 

 

71,317

 

Other long-term assets

 

 

33,388

 

 

 

25,705

 

Total assets

 

$

925,315

 

 

$

458,629

 

Liabilities and shareholders’ equity

 

 

 

 

Current liabilities

 

 

 

 

Accounts payable

 

$

58,357

 

 

$

27,598

 

Current portion of long-term debt

 

 

1,250

 

 

 

 

Current portion of finance lease liability

 

 

708

 

 

 

652

 

Other current liabilities

 

 

104,908

 

 

 

55,374

 

Total current liabilities

 

 

165,223

 

 

 

83,624

 

Long-term debt

 

 

93,107

 

 

 

 

Long-term portion of finance lease liability

 

 

18,532

 

 

 

19,239

 

Other long-term liabilities

 

 

49,723

 

 

 

18,906

 

Total liabilities

 

 

326,585

 

 

 

121,769

 

Contingencies

 

 

 

 

Shareholders’ equity

 

 

 

 

Common shares $0.10 par value; 100,000 shares authorized; 37,165 and 20,162 issued and outstanding as of December 31, 2023 and 2022, respectively

 

 

3,717

 

 

 

2,016

 

Additional paid-in capital

 

 

746,450

 

 

 

334,969

 

Retained earnings (accumulated deficit)

 

 

(150,144

)

 

 

1,251

 

Accumulated other comprehensive loss

 

 

(1,293

)

 

 

(1,376

)

Total shareholders’ equity

 

 

598,730

 

 

 

336,860

 

Total liabilities and shareholders’ equity

 

$

925,315

 

 

$

458,629

 

ORTHOFIX MEDICAL INC.
Non-GAAP Financial Measures

The following tables present reconciliations of various financial measures calculated in accordance with U.S. generally accepted accounting principles (“GAAP”), to various non-GAAP financial measures that exclude (or in the case of free cash flow, include) items specified in the tables. The GAAP measures shown in the tables below represent the most comparable GAAP measure to the applicable non-GAAP measure(s) shown in the table. For further information regarding the nature of these exclusions, why the Company believes that these non-GAAP financial measures provide useful information to investors, the specific manner in which management uses these measures, and some of the limitations associated with the use of these measures, please refer to the Company's Current Report on Form 8-K regarding this press release filed today with the SEC available on the SEC's website at www.sec.gov and on the “Investors” page of the Company’s website at www.orthofix.com.

Adjusted Gross Profit and Adjusted Gross Margin

 

 

Three Months Ended December 31,

(Unaudited, U.S. Dollars, in thousands)

 

2023

 

 

Orthofix
2022

 

SeaSpine
2022

 

Pro Forma
2022

Gross profit

 

$

136,630

 

 

$

89,176

 

 

$

38,515

 

 

$

127,691

 

Share-based compensation expense

 

 

462

 

 

 

217

 

 

 

102

 

 

 

319

 

SeaSpine merger-related costs

 

 

214

 

 

 

 

 

 

 

 

 

 

Strategic investments

 

 

125

 

 

 

439

 

 

 

 

 

 

439

 

Acquisition-related fair value adjustments

 

 

7,037

 

 

 

 

 

 

 

 

 

 

Amortization/Depreciation of Acquired Long-Lived Assets

 

 

372

 

 

 

 

 

 

 

 

 

 

Medical device regulation

 

 

(72

)

 

 

1

 

 

 

 

 

 

1

 

Adjusted gross profit

 

$

144,768

 

 

$

89,833

 

 

$

38,617

 

 

$

128,450

 

Adjusted gross margin

 

 

72.2

%

 

 

73.5

%

 

 

60.2

%

 

 

68.9

%

             

 

 

Year Ended December 31,

(Unaudited, U.S. Dollars, in thousands)

 

2023

 

 

Orthofix
2022

 

SeaSpine
2022

 

Pro Forma
2022

Gross profit

 

$

486,273

 

 

$

337,169

 

 

$

141,834

 

 

$

479,003

 

Share-based compensation expense

 

 

1,878

 

 

 

827

 

 

 

365

 

 

 

1,192

 

SeaSpine merger-related costs

 

 

6,861

 

 

 

 

 

 

 

 

 

 

Strategic investments

 

 

389

 

 

 

1,334

 

 

 

 

 

 

1,334

 

Acquisition-related fair value adjustments

 

 

36,044

 

 

 

 

 

 

208

 

 

 

208

 

Amortization/Depreciation of Acquired Long-Lived Assets

 

 

1,196

 

 

 

 

 

 

 

 

 

 

Medical device regulation

 

 

604

 

 

 

15

 

 

 

 

 

 

15

 

Adjusted gross profit

 

$

533,245

 

 

$

339,345

 

 

$

142,407

 

 

$

481,752

 

Adjusted gross margin

 

 

71.4

%

 

 

73.7

%

 

 

59.3

%

 

 

68.7

%

                 

Adjusted EBITDA

 

 

Three Months Ended December 31,

(Unaudited, U.S. Dollars, in thousands)

 

2023

 

 

 

Orthofix
2022

 

 

 

SeaSpine
2022

 

 

Pro Forma
2022

Loss before income taxes

 

$

(22,049

)

 

 

$

(6,987

)

 

 

$

(20,287

)

 

 

$

(27,274

)

Interest expense, net

 

 

4,500

 

 

 

 

229

 

 

 

 

202

 

 

 

 

431

 

Depreciation and amortization

 

 

13,969

 

 

 

 

7,421

 

 

 

 

4,349

 

 

 

 

11,770

 

Share-based compensation expense

 

 

3,167

 

 

 

 

4,923

 

 

 

 

3,412

 

 

 

 

8,335

 

Foreign exchange impact

 

 

(2,638

)

 

 

 

(4,195

)

 

 

 

(147

)

 

 

 

(4,342

)

SeaSpine merger-related costs

 

 

2,261

  

 

 

9,073

  

 

 

2,616

 

 

 

 

11,689

 

Strategic investments

 

 

389

 

 

 

 

771

 

 

 

 

(16

)

 

 

 

755

 

Acquisition-related fair value adjustments

 

 

6,486

 

 

 

 

200

 

 

 

 

 

 

 

 

200

 

(Gain) loss on investments

 

 

1,781

 

 

 

 

 

 

 

 

 

 

 

 

 

Litigation and investigation costs

 

 

8,842

 

 

 

 

337

 

 

 

 

1,066

 

 

 

 

1,403

 

Medical device regulation

 

 

1,927

 

 

 

 

3,481

 

 

 

 

 

 

 

 

3,481

 

Business interruption - COVID-19

 

 

 

 

 

 

513

 

 

 

 

 

 

 

 

513

 

Succession charges

 

 

1,006

 

 

 

 

 

 

 

 

 

 

 

 

 

Spinal set instrument replacement expense

 

 

 

 

 

 

 

 

 

 

2,630

 

 

 

 

2,630

 

European sales and marketing organization restructuring

 

 

 

 

 

 

 

 

 

 

426

 

 

 

 

426

 

Adjusted EBITDA

 

$

19,641

 

 

 

$

15,766

 

 

 

$

(5,749

)

 

 

$

10,017

 

                  
                  

 

 

Year Ended December 31,

(Unaudited, U.S. Dollars, in thousands)

 

2023

 

 

 

Orthofix
2022

 

 

 

SeaSpine
2022

 

 

Pro Forma
2022

Loss before income taxes

 

$

(148,679

)

 

 

$

(17,706

)

 

 

$

(67,324

)

 

 

$

(85,030

)

Interest expense, net

 

 

8,631

 

 

 

 

1,288

 

 

 

 

644

 

 

 

 

1,932

 

Depreciation and amortization

 

 

53,063

 

 

 

 

29,019

 

 

 

 

17,187

 

 

 

 

46,206

 

Share-based compensation expense

 

 

35,707

 

 

 

 

18,443

 

 

 

 

13,584

 

 

 

 

32,027

 

Foreign exchange impact

 

 

(1,581

)

 

 

 

3,291

 

 

 

 

387

 

 

 

 

3,678

 

SeaSpine merger-related costs

 

 

36,623

 

 

 

 

12,010

 

 

 

 

4,028

 

 

 

 

16,038

 

Strategic investments

 

 

2,272

 

 

 

 

4,018

 

 

 

 

362

 

 

 

 

4,380

 

Acquisition-related fair value adjustments

 

 

33,393

 

 

 

 

(15,595

)

 

 

 

208

 

 

 

 

(15,387

)

(Gain) loss on investments

 

 

1,781

 

 

 

 

188

 

 

 

 

 

 

 

 

188

 

Litigation and investigation costs

 

 

14,453

 

 

 

 

803

 

 

 

 

1,610

 

 

 

 

2,413

 

Medical device regulation

 

 

9,446

 

 

 

 

10,261

 

 

 

 

 

 

 

 

10,261

 

Business interruption - COVID-19

 

 

 

 

 

 

2,387

 

 

 

 

 

 

 

 

2,387

 

Succession charges

 

 

1,176

 

 

 

 

146

 

 

 

 

 

 

 

 

146

 

Spinal set instrument replacement expense

 

 

 

 

 

 

 

 

 

 

7,179

 

 

 

 

7,179

 

European sales and marketing organization restructuring

 

 

 

 

 

 

 

 

 

 

984

 

 

 

 

984

 

Adjusted EBITDA

 

$

46,285

 

 

 

$

48,553

 

 

 

$

(21,151

)

 

 

$

27,402

 

                    

Cash Flow and Free Cash Flow

 

 

Year Ended December 31,

(Unaudited, U.S. Dollars, in thousands)

 

2023

 

 

 

Orthofix
2022

 

 

SeaSpine
2022

 

 

Pro Forma
2022

Net cash from operating activities

 

$

(45,753

)

 

 

$

(11,538

)

 

 

$

(38,157

)

 

 

$

(49,695

)

Net cash from investing activities

 

 

(33,131

)

 

 

 

(24,534

)

 

 

 

(40,325

)

 

 

 

(64,859

)

Net cash from financing activities

 

 

65,322

 

 

 

 

(78

)

 

 

 

24,654

 

 

 

 

24,576

 

Effect of exchange rate changes on cash

 

 

619

 

 

 

 

(997

)

 

 

 

140

 

 

 

 

(857

)

Net change in cash, cash equivalents, and restricted cash

 

$

(12,943

)

 

 

$

(37,147

)

 

 

$

(53,688

)

 

 

$

(90,835

)

   

 

 

Year Ended December 31,

(Unaudited, U.S. Dollars, in thousands)

 

2023

 

 

 

Orthofix
2022

 

 

SeaSpine
2022

 

 

Pro Forma
2022

Net cash from operating activities

 

$

(45,753

)

 

 

$

(11,538

)

 

 

$

(38,157

)

 

 

$

(49,695

)

Capital expenditures

 

 

(62,050

)

 

 

 

(23,160

)

 

 

 

(37,752

)

 

 

 

(60,912

)

Free cash flow

 

$

(107,803

)

 

 

$

(34,698

)

 

 

$

(75,909

)

 

 

$

(110,607

)

                    

Net Income and EPS

 

 

Three Months Ended December 31,

(Unaudited, U.S. Dollars, in thousands, except share and per share data)

 

2023

 

 

 

Orthofix
2022

 

 

SeaSpine
2022

 

 

Pro Forma
2022

Net loss

 

$

(22,174

)

 

 

$

(7,062

)

 

 

$

(18,958

)

 

 

$

(26,020

)

Weighted average shares outstanding (in millions)

 

 

37.3

 

 

 

 

20.2

 

 

 

 

15.4

 

 

 

 

35.6

 

EPS

 

$

(0.59

)

 

 

$

(0.35

)

 

 

$

(1.23

)

 

 

$

(0.73

)

   

 

 

Year Ended December 31,

(Unaudited, U.S. Dollars, in thousands, except share and per share data)

 

2023

 

 

 

Orthofix
2022

 

 

SeaSpine
2022

 

 

Pro Forma
2022

Net loss

 

$

(151,395

)

 

 

$

(19,749

)

 

 

$

(65,009

)

 

 

$

(84,758

)

Weighted average shares outstanding

 

 

36.7

 

 

 

 

20.1

 

 

 

 

15.4

 

 

 

 

35.5

 

EPS

 

$

(4.12

)

 

 

$

(0.98

)

 

 

$

(4.22

)

 

 

$

(2.39

)

 

Assertio

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB